Overview

A Study of Safety and Pharmacokinetics of Repeated Dose of Micafungin as Antifungal Prophylaxis in Children and Adolescents Who Undergo Hematopoietic Stem Cell Transplant

Status:
Completed
Trial end date:
2009-03-01
Target enrollment:
Participant gender:
Summary
The study will evaluate PK and safety of two dose levels of Micafungin (FK463) as Antifungal prophylaxis in children and adolescents undergoing HSCT
Phase:
Phase 1
Details
Lead Sponsor:
Astellas Pharma Inc
Treatments:
Antifungal Agents
Echinocandins
Micafungin
Miconazole